Sheila Gujrathi

Board Director

Director

Ventyx Biosciences, Inc.Janux Therapeutics, Inc.

Insider activity · 24 months1 buy0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 1 buy · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (1 ops.)

€288k

▼ Sales (0 ops.)

—

Latest filing published 04 Mar 2026 for Ventyx Biosciences, Inc.. Read the official filing

Filing timeline

BuySale

Sheila Gujrathi

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Sheila Gujrathi: trading record in brief

Filings by Sheila Gujrathi span 2 companies, the busiest being Janux Therapeutics, Inc. and Ventyx Biosciences, Inc. Between 25 October 2021 and 4 March 2026, the trades on record add up to 8 filings.

Every open-market trade on record is a purchase: 1 purchase worth €288k, and no sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 2 share grants and 1 option exercise.

Most recently, on 4 March 2026, the filings show a transaction in Ventyx Biosciences, Inc. The most recent open-market purchase was published on 26 December 2024, 661 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.